About

We are dedicated to improving public health by impacting the social problem of addiction. SafeMedWaste provides an easy-to-use, safe, environmentally-friendly and cost-effective solution that completely destroys controlled substances* at their source.

Our Company

Founded in 2018, Okra Medical is headquartered on Johns Island, South Carolina. We specialize in product development with an initial focus on disposal solutions for controlled pharmaceutical substances*.

Okra Medical’s patent-pending SafeMedWaste formulation neutralizes and chemically destroys controlled substances* (including opioids) to render them non-retrievable. SafeMedWaste helps relieve DEA registrants of controlled substances—such as opioid manufacturers, hospitals, surgery centers and law enforcement agencies—of the burden, expense and liability of reverse distribution and the highly expensive process of safely moving discarded opioids to incinerators and landfills.

Ease of use is at the forefront of our product development. Authorized personnel simply dispose discarded controlled substances into SafeMedWaste containers, similar to how one discards syringes. No further human effort is required to render controlled substances* inactive.

Okra Medical is a strategic sourcing partner to hospitals, hospice facilities, law enforcement agencies, pharmaceutical manufacturers, and veterinary care clinics.

Our Mission

Our mission is to improve public health by bridging science and innovation.

We are dedicated to impacting the social problem of addiction to controlled substances* by attacking the problem at its source. We believe preventing even one person from going down the path of drug addiction is one step to a larger victory for society.

Our Leadership

Okra Medical is led by a team of successful business executives, product innovators, scientific thought leaders and technologists, and an advisory board. Collectively, we are working to bring new innovations to market in the pharmaceutical waste disposal sector.

Marshall Hartmann

Chief Executive Officer

Marshall Hartmann brings passion and an inextinguishable enthusiasm to the Okra team.  A South Carolina native, Marshall quickly established a successful career in banking after graduating from the University of South Carolina with a degree in finance. He leveraged that experience to launch a new career in residential and commercial development where he focused his efforts for nearly 30 years.  Over the past decade, Marshall and his brother have started two companies, Okra Medical and an innovative electronics manufacturer that has sustained 50% growth each year.

Marshall Hartmann

Chief Executive Officer

Marshall Hartmann brings passion and an inextinguishable enthusiasm to the Okra team.  A South Carolina native, Marshall quickly established a successful career in banking after graduating from the University of South Carolina with a degree in finance. He leveraged that experience to launch a new career in residential and commercial development where he focused his efforts for nearly 30 years.  Over the past decade, Marshall and his brother have started two companies, Okra Medical and an innovative electronics manufacturer that has sustained 50% growth each year.

Justin Stas

Chief Technology Officer

By the time Justin Stas began pursuing a degree in biomedical engineering, he already spent more than a decade learning about anesthesia and pain management from his father, a thought leader in these fields. Throughout his studies, Justin developed an expertise on the intricacies of chemical compounds. After his formal studies, he spent years tirelessly pursuing a formula to neutralize controlled substances. Much of his research was conducted in tandem with a multi-disciplinary team that has years of cumulative experience in pharmaceutical research. With the launch of Okra Medical, Justin is experiencing his mission of improving humanity through innovation.

Justin Stas

Chief Technology Officer

By the time Justin Stas began pursuing a degree in biomedical engineering, he already spent more than a decade learning about anesthesia and pain management from his father, a thought leader in these fields. Throughout his studies, Justin developed an expertise on the intricacies of chemical compounds. After his formal studies, he spent years tirelessly pursuing a formula to neutralize controlled substances. Much of his research was conducted in tandem with a multi-disciplinary team that has years of cumulative experience in pharmaceutical research. With the launch of Okra Medical, Justin is experiencing his mission of improving humanity through innovation.

Dr. John Stas

Chief Medical Officer

Dr. John Stas is a retired Army Officer that has decades of acute pain management experience. He has led anesthesia departments to reduce opioid consumption with alternative pain management methods. Additionally, he spent ten years in civil service as both an anesthesia leader and developing a state-of-the-art pain management practice for combat casualties. Dr. Stas has been teaching advanced regional anesthesia both clinically and didactically for many years in multiple areas to include the University of South Carolina Anesthesia Program and holds a faculty position for Twin Oaks Anesthesia. He is an expert with ultrasonography in the field of regional anesthesia and acute pain management.  Dr. Stas graduated from the Medical University of South Carolina and received both a master’s degree from the U.S Army Graduate Program in Anesthesia and a Doctorate from Texas Wesleyan University.

Dr. John Stas

Chief Medical Officer

Dr. John Stas is a retired Army Officer that has decades of acute pain management experience. He has led anesthesia departments to reduce opioid consumption with alternative pain management methods. Additionally, he spent ten years in civil service as both an anesthesia leader and developing a state-of-the-art pain management practice for combat casualties. Dr. Stas has been teaching advanced regional anesthesia both clinically and didactically for many years in multiple areas to include the University of South Carolina Anesthesia Program and holds a faculty position for Twin Oaks Anesthesia. He is an expert with ultrasonography in the field of regional anesthesia and acute pain management.  Dr. Stas graduated from the Medical University of South Carolina and received both a master’s degree from the U.S Army Graduate Program in Anesthesia and a Doctorate from Texas Wesleyan University.

Edward Hartmann

Chief Financial Officer

Ed Hartmann brings more than 30 years of experience in financial management, leadership and consulting to the Okra Medical team.  Ed previously served as V. P. and Controller for Curacao International Trust Corporation in St. Thomas and more recently as the V.P. of Finance for Crowley Maritime, Inc., a $2 billion ocean freight transportation and logistics company. Ed received a Bachelor of Science degree in International Finance from Florida State University and an MBA and DBA in organizational leadership.  Ed thrives at optimizing financial performance, raising debt and equity capital, strategic planning, and integrating acquisitions.

Edward Hartman

Chief Financial Officer

Ed Hartmann brings more than 30 years of experience in financial management, leadership and consulting to the Okra Medical team.  Ed previously served as V. P. and Controller for Curacao International Trust Corporation in St. Thomas and more recently as the V.P. of Finance for Crowley Maritime, Inc., a $2 billion ocean freight transportation and logistics company. Ed received a Bachelor of Science degree in International Finance from Florida State University and an MBA and DBA in organizational leadership.  Ed thrives at optimizing financial performance, raising debt and equity capital, strategic planning, and integrating acquisitions.

Board of Advisors

Mark Harvill, CEO Avomeen Analytical

Mark has held leadership positions in global contract research organizations (CROs) for the past 23 years. Throughout Mark’s CRO career, his teams have developed industry-leading client relationships teams to support approvals for numerous blockbuster drugs and medical devices, including three of the world’s top-selling drugs.  As the leader of Avomeen, Mark works closely with the senior leadership and project teams to ensure the company delivers exceptional and innovative hard-to-solve product development challenges, while ensuring compliance with rigorous regulatory standards such as cGMP, cGLP and other industry standards.

Andrew Kolbert, PhD, M.T.M., President and CEO, Avomeen Analytical

Andrew has 20 years of experience executing and managing analytical and product development programs, both internally and in external organizations.  His expertise is analytical chemistry in highly regulated areas including pharmaceutical development and testing, food contact migration studies, extractables and leachables studies, food additive and food contact notification testing and registration, and pesticide and insecticide testing under FIFCA.  He has served as an expert witness to support litigation in the areas of pharmaceutical development and analytical testing.  He has participated in FDA pre-notification conferences, FDA site audits, and trained FDA inspectors on analytical technology.

David Wanetick, CEO, IncreMental Advantage

David is the CEO of Incremental Advantage. He is recognized world-wide for his expertise in valuing emerging technologies and intangible assets such as patents, trademarks, copyrights, contracts, earn-outs and non-compete agreements. His clients include emerging, mid- and large-sized companies; technology transfer offices; inventors; venture capitalists and private equity firms. David is the author of seven books. The most recent of which are Plight of the Patentee, Solution Nation: One Nation is Disproportionately Responding to the World ‘s Most Intractable Problems, The Strategic Negotiator: A Manual for Negotiating at the Elite Level, and Business Model Validation.

Sustainability

Okra Medical is a leading proponent for the development of environmentally responsible solutions for the disposal and destruction of controlled substance* waste.  In fact, since SafeMedWaste reduces controlled substances* to their basic elements, the formulation is environmentally friendly. Neither our proprietary formulation nor the denatured controlled substances* leach into landfills.

* Certain controlled substances that are also regulated by the EPA are pending EPA concurrance.